Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$72.33 USD

72.33
2,236,603

+1.96 (2.79%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $72.35 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.

3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of April 3, 2023

by Panel Of Zacks Experts

An Interesting AI Technology Stock and a Health Care Products Distributor for Your Review.

Here's What Makes UnitedHealth Group (UNH) a Lucrative Bet Now

by Zacks Equity Research

UnitedHealth Group (UNH) is well-poised for growth on the back of a growing customer base within its government businesses, efficient telehealth services and solid cash-generating abilities.

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Medtronic (MDT) Launches New Venture to Treat Kidney Failure

by Zacks Equity Research

Medtronic's (MDT) new venture is dedicated to reshaping kidney health and driving patient-centered technology solutions.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays

by Zacks Equity Research

Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.

Why You Should Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.

Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

HSIC vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

HSIC vs. ALGN: Which Stock Is the Better Value Option?

PacBio (PACB) New Revio Workflows to Boost Agricultural Output

by Zacks Equity Research

PacBio (PACB), in collaboration with Corteva Agriscience, is likely to enable groundbreaking plant and microbial long-read sequencing workflow on Revio system.

Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials

by Zacks Equity Research

Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.

QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award

by Zacks Equity Research

QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its planned geographic expansion.

Illumina (ILMN) to Enable Tertiary Analysis With New Launch

by Zacks Equity Research

Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB

by Zacks Equity Research

Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution during fiscal Q2.

Is Henry Schein (HSIC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels

by Zacks Equity Research

Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers

Here's Why You Should Retain Inogen (INGN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.